Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep demonstrates 69% ORR in pancreatic cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 22, 2023 10:33am

95 Views

Post# 35695236

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancer

TCRs typically recognise antigen within the context of an MHC molecule and the expansion of cytotoxic CD8+ immune effector T cells

ONCY Aware-1 and Bracelet-1 breast cancer clinical studies tat treatment with pelareorep demonstrated the expansion of cytotoxic CD8+ immune effector T cells vs immunosuppressive Treg cells.

In so doing, ONCY showed how pelareorep is able to remodel the tumor microenvironment (TME) and turn cold tumors, like pancreatic cancer, into ‘hot’ inflamed tumors that are demonstrate high responses to immune checkpoint inhibitors (CPIs).

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec